What is Pfizer's oncology biosimilars — revenues:?

Pfizer (PFE) reported oncology biosimilars — revenues: of $409.00M in Q1 2026.

How has Pfizer's oncology biosimilars — revenues: changed year-over-year?

Pfizer's oncology biosimilars — revenues: increased by 54.9% year-over-year, from $264.00M to $409.00M.

What is the long-term trend for Pfizer's oncology biosimilars — revenues:?

Over 3 years (2022 to 2025), Pfizer's oncology biosimilars — revenues: has grown at a -9.5% compound annual growth rate (CAGR), from $1.75B to $1.30B.

Products & Services · Revenues:

Oncology Biosimilars — Revenues:

Pfizer Oncology Biosimilars — Revenues: increased by 10.8% to $409.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 54.9%, from $264.00M to $409.00M. Over 3 years (FY 2022 to FY 2025), Oncology Biosimilars — Revenues: shows a downward trend with a -9.5% CAGR.

Analysis

StatementSegment

First reportedQ1 2022

Last reportedQ1 2026May 5, 2026

Rolls up toTotal Revenue

Metric ID: pfe_segment_oncology_biosimilars_revenues

Historical Data

17 periods

	Q1 '22	Q2 '22	Q3 '22	Q4 '22	Q1 '23	Q2 '23	Q3 '23	Q4 '23	Q1 '24	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Value	$438.25M	$438.25M	$438.25M	$438.25M	$412.00M	$363.00M	$310.00M	$322.00M	$264.00M	$279.00M	$285.00M	$209.00M	$264.00M	$353.00M	$315.00M	$369.00M	$409.00M
QoQ Change	—	+0.0%	+0.0%	+0.0%	-6.0%	-11.9%	-14.6%	+3.9%	-18.0%	+5.7%	+2.2%	-26.7%	+26.3%	+33.7%	-10.8%	+17.1%	+10.8%
YoY Change	—	—	—	—	-6.0%	-17.2%	-29.3%	-26.5%	-35.9%	-23.1%	-8.1%	-35.1%	+0.0%	+26.5%	+10.5%	+76.6%	+54.9%

Range$209.00M – $438.25M

CAGR-1.7%

Avg YoY Growth-1.0%

Median YoY Growth-8.1%

Current Streak2 quarters growth

Frequently Asked Questions

What is Pfizer's oncology biosimilars — revenues:?: Pfizer (PFE) reported oncology biosimilars — revenues: of $409.00M in Q1 2026.
How has Pfizer's oncology biosimilars — revenues: changed year-over-year?: Pfizer's oncology biosimilars — revenues: increased by 54.9% year-over-year, from $264.00M to $409.00M.
What is the long-term trend for Pfizer's oncology biosimilars — revenues:?: Over 3 years (2022 to 2025), Pfizer's oncology biosimilars — revenues: has grown at a -9.5% compound annual growth rate (CAGR), from $1.75B to $1.30B.